Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme

European Journal of Surgical Oncology

Volumn 36, Issue 2, 2010, Pages 201-207

  Schuhmann, M U ^a   Zucht, H D ^b   Nassimi, R ^a   Heine, G ^b   Schneekloth, C G ^a   Stuerenburg, H J ^c   Selle, H ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Digilab BioVisioN GmbH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Biomarker; Cerebrospinal fluid; Glioblastoma; Neurosurgery; Peptidomics

Indexed keywords

ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; OSTEOPONTIN; PREALBUMIN;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MASS SPECTROMETRY; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SCREENING;

ADULT; AGED; ALBUMINS; ALPHA 1-ANTICHYMOTRYPSIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PEPTIDE FRAGMENTS; PEPTIDES; PREALBUMIN; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUPRATENTORIAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 74149085854     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2009.07.010     Document Type: Article

References (30)

1. Schulz-Knappe P., Zucht H.D., Heine G., et al. Peptidomics: the comprehensive analysis of peptides in complex biological mixtures. Comb Chem High Throughput Screen 4 (2001) 207-217
2. Lamerz J., Selle H., Scapozza L., et al. Correlation-associated peptide networks of human cerebrospinal fluid. Proteomics 5 (2005) 2789-2798
3. Tammen H., Hess R., Schulte I., et al. Prerequisites for peptidomic analysis of blood samples: II. Analysis of human plasma after oral glucose challenge - a proof of concept. Comb Chem High Throughput Screen 8 (2005) 735-741
4. Tammen H., Schulte I., Hess R., et al. Prerequisites for peptidomic analysis of blood samples: I. Evaluation of blood specimen qualities and determination of technical performance characteristics. Comb Chem High Throughput Screen 8 (2005) 725-733
5. Zheng P.P., Luider T.M., Pieters R., et al. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 62 (2003) 855-862
6. Schrader M., and Schulz-Knappe P. Peptidomics technologies for human body fluids. Trends Biotechnol 19 (2001) S55-S60
7. Sickmann A., Dormeyer W., Wortelkamp S., et al. Towards a high resolution separation of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 770 (2002) 167-196
8. Noben J.P., Dumont D., Kwasnikowska N., et al. Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J Proteome Res 5 (2006) 1647-1657
9. Zhang J., Goodlett D.R., Peskind E.R., et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 26 (2005) 207-227
10. Papadopoulos M.C., Saadoun S., Davies D.C., and Bell B.A. Emerging molecular mechanisms of brain tumour oedema. Br J Neurosurg 15 (2001) 101-108
11. Roberts H.C., Roberts T.P., Brasch R.C., and Dillon W.P. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. Am J Neuroradiol 21 (2000) 891-899
12. Schneider S.W., Ludwig T., Tatenhorst L., et al. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol 107 (2004) 272-276
13. Banks W.A., and Kastin A.J. Passage of peptides across the blood-brain barrier: pathophysiological perspectives. Life Sci 59 (1996) 1923-1943
14. Kastin A.J., Pan W., Maness L.M., and Banks W.A. Peptides crossing the blood-brain barrier: some unusual observations. Brain Res 848 (1999) 96-100
15. Kremer P., Wunder A., Sinn H., et al. Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results. Neurol Res 22 (2000) 481-489
16. Ichioka T., Miyatake S.I., Asai N., et al. Enhanced detection of malignant glioma xenograft by fluorescein-human serum albumin conjugate. J Neurooncol 67 (2004) 47-52
17. Rittling S.R., and Denhardt D.T. Osteopontine function in pathology: lessons from osteopontine-deficient mice. Exp Nephrol 7 (1999) 103-113
18. Coppola D., Szabo M., Boulware D., et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10 (2004) 184-190
19. Markert J.M., Fuller C.M., Gillespie G.Y., et al. Differential gene expression profiling in human brain tumors. Physiol Genomics 5 (2001) 21-33
20. Takano S., Tsuboi K., Tomono Y., Mitsui Y., and Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer 82 (2000) 1967-1973
21. Ding Q., Stewart Jr. J., Prince C.W., et al. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 62 (2002) 5336-5343
22. Wang D.Y., Yamamoto S., Hijiya N., Benveniste E.N., and Gladson C.L. Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions. Oncogene 19 (2000) 5801-5809
23. Kao C.L., Chiou S.H., Ho D.M., et al. Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor. Am J Clin Pathol 123 (2005) 297-304
24. Abraham C.R., Shirahama T., and Potter H. Alpha 1-antichymotrypsin is associated solely with amyloid deposits containing the beta-protein. Amyloid and cell localization of alpha 1-antichymotrypsin. Neurobiol Aging 11 (1990) 123-129
25. Ng H.K., and Lo S.T. Immunostaining for alpha 1-antichymotrypsin and alpha 1-antitrypsin in gliomas. Histopathology 13 (1988) 79-87
26. Kroh H., and Cervosnavarro J. Alpha-1-antichymotrypsin in human glioblastoma-multiforme cells and its relation to GFAP immunostaining. Clin Neuropathol 10 (1991) 181-186
27. Foekens J.A., Buessecker F., Peters H.A., et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55 (1995) 1423-1427
28. Umeda T., Eguchi Y., Okino K., Kodama M., and Hattori T. Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol 183 (1997) 388-397
29. Herbert J., Wilcox J.N., Pham K.T., et al. Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology 36 (1986) 900-911
30. Lignelid H., Collins V.P., and Jacobsson B. Cystatin C and transthyretin expression in normal and neoplastic tissues of the human brain and pituitary. Acta Neuropathologica 93 (1997) 494-500